XTL Biopharmaceuticals Ltd.
XTLB | NASDAQ
$2.38
-$0.02 (-0.83%)
At close: Sep 21, 2026, 4:00 PM ET
$2.22
-$0.16 (-6.72%)
After-hours:
Sep 21, 2026, 7:30 PM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | 451K | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | 448K | n/a | 1K | 1K | 1K |
Gross Profit | n/a | 3K | n/a | -1K | -1K | -1K |
Operating Income | -1.69M | -2.17M | -765K | -880K | -1.03M | -948K |
Interest Income | 60K | 34K | 41K | 36K | 8K | 33K |
Pretax Income | -759K | -1.16M | -1.78M | -1.35M | 435K | -2.95M |
Net Income | -6.97M | -1.03M | -1.78K | -1.35M | 435K | -782K |
Selling & General & Admin | 1.13M | 2.05M | 734K | 850K | 1M | 910K |
Research & Development | 28K | 98K | 31K | 30K | 30K | 38K |
Other Expenses | 531K | 31K | n/a | n/a | n/a | n/a |
Operating Expenses | 1.69M | 2.18M | 765K | 880K | 1.03M | 948K |
Interest Expense | 7K | 86K | 4K | 11K | 21K | 17K |
Selling & Marketing Expenses | n/a | 178K | n/a | n/a | n/a | n/a |
Cost & Expenses | 1.69M | 2.62M | 765K | 880K | 1.03M | 948K |
Income Tax Expense | n/a | -130K | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 420.65K | 420.65K | 340.57K | 340.57K | 332.5K | 321.38K |
Shares Outstanding (Diluted) | 440.1K | 440.1K | 340.57K | 340.57K | 384.72K | 321.38K |
EPS (Basic) | -17 | -2.40 | -30 | -4 | 1.28 | -9.12 |
EPS (Diluted) | -16 | -2.40 | -30 | -4 | 1.12 | -9.12 |
EBITDA | -752K | -930K | -764K | -879K | -1.03M | -947K |
EBIT | -752K | -1.13M | -765K | -880K | -1.03M | -948K |
Depreciation & Amortization | n/a | 199K | 1K | 1K | 1K | 1K |
Add to Watchlist
Select watchlists to add or remove XTLB